NanoCarrier's FVIIa alliance hits bump but cisplatin tie-up forges ahead
This article was originally published in Scrip
Executive Summary
Around a year after they extended an initial 2010 option and research collaboration, the French state-owned company LFB Biotechnologies and the Japanese bioventure NanoCarrier have temporarily ended their attempts to develop a novel sustained-release formulation of LFB's human Factor VIIa product for hemophilia.